Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press200ArticlesСтатьиInterferon a and γ in the serum of primary bone tumors patientsИнтерфероны альфа и гамма в сыворотке крови больных первичными опухолями костейБабкинаИ. В.
Russian Federation
КушлинскийН. Е.
Russian Federation
biochimia@mtv-net.ruСоловьевЮ. Н.
Russian Federation
КостьлеваО. И.
Russian Federation
Ма- ЧакГ. Н.
Russian Federation
АлиевМ. Д.
Russian Federation
BabkinaI. V.
Russian Federation
KushlinskyN. E.
Russian Federation
SolovievYu. N.
Russian Federation
KostilevaO. I.
Russian Federation
MachakG. N.
Russian Federation
AlievM. D.
Russian Federation
Российский онкологический научный центр им. Н.Н. Блохина РАМНN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences1101201131555811012022Copyright ©; 2011, ., ., ., ., ., ., Babkina I.V., Kushlinsky N.E., Soloviev Y.N., Kostileva O.I., Machak G.N., Aliev M.D.Copyright ©; 2011, Бабкина И.В., Кушлинский Н.Е., Соловьев Ю.Н., Костьлева О.И., Ма- Чак Г.Н., Алиев М.Д., Babkina I., Kushlinsky N., Soloviev Y., Kostileva O., Machak G., Aliev M.2011., ., ., ., ., ., Babkina I.V., Kushlinsky N.E., Soloviev Y.N., Kostileva O.I., Machak G.N., Aliev M.D.Бабкина И.В., Кушлинский Н.Е., Соловьев Ю.Н., Костьлева О.И., Ма- Чак Г.Н., Алиев М.Д., Babkina I., Kushlinsky N., Soloviev Y., Kostileva O., Machak G., Aliev M.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/200

Serum levels of interferon γ (IF-γ) in healthy donors and in patients with benign bone neoplasms were significantly high comparing to borderline and malignant bone tumors. No reliable distinguishes were found between serum levels of IF-α in patients with benign, borderline and malignant bone tumors. Invert correlation was shown between age and serum level of IF-α in healthy donors, on the contrary no correlations were observed between age and serum levels of IF-γ and of IF-α in patients with bone neoplasms. and also serum IF-γ and IF-α levels in patients with bone sarcomas are not dependant on the tumors histology and on the size of primary bone tumors. No correlations were found in the levels of IF-α and IF-γ in patients with localized and metastatic tumor processes. direct correlation was found between IF-α and IF-γ serum levels in patients with malignant bone tumors in condition of maximal IF-concentrations in blood serum and advanced tumors.

Содержание ИФН-γ в сыворотке крови практически здоровых людей и пациентов с доброкачественными новообразованиями костей было достоверно выше, чем с пограничными и злокачественными опухолями. Не выявлено достоверных различий в уровнях ИФН-α в сыворотке крови больных доброкачественными, пограничными и злокачественными опухолями костей. У практически здоровых людей выявлена обратная корреляция между возрастом и содержанием ИФН-α в сыворотке крови, а при опухолях костей взаимосвязи между возрастом пациентов и содержанием ИФН-γ и ИФН-α не выявлено. Содержание ИФН-γ и ИФН-α при саркомах костей не зависело от гистологического строения новообразования. У пациентов с метастазами и с локализованной формой заболевания уровни ИФН-γ и ИФН-α в сыворотке крови достоверно не различались. Достоверных различий в содержании ИФН-γ и ИФН-α в сыворотке крови больных с учетом максимального размера первичной опухоли не выявлено. Корреляционный анализ показал наличие прямой корреляционной зависимости между содержанием ИФН-γ и ИФН-α в сыворотке крови больных злокачественными опухолями костей с максимальными показателями при генерализации опухолевого процесса.

interferon αinterferon γblood serumbone tumorsинтерферон-αинтерферон-γсывороткаопухоли костейBaron S., Hernandez J., Bekisz J. et al. Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro. J. Interferon Cytokine Res. 2007, v. 27, No. 2, p. 157-163.Boye K., Andersen K., Tveito S. et al. Interferon-gamma-induced sup-pression of S100A4 transcription is mediated by the class II transactivator. Tumour Biol. 2007, v. 28, No. 1, p. 27-35.Gimeno R., Lee C.K., Schindler C., Levy D.E. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol. Cell Biol. 2005, v. 13, p. 5456-5465.Inaba H., Glibetic M., Buck S. et al. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by upregulating Fas receptors and caspase-8. Pediatr. Blood Cancer. 2004, v. 43, No. 7, p. 729-736.Inaba H., Glibetic M., Buck S. et al. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by upregulating Fas receptors and caspase-8. Pediatr. Blood Cancer. 2004, v. 43, No. 7, p. 729-736.Meda L., Gasperini S., Ceska M., Cassatella M.A. Modulation of proinflammatory cytokine release from human polymorphonuclear leukocytes by gamma interferon. Cell Immunol. 1994, v. 157, No. 2, p. 448-461.Nishimura M., Yuasa K., Mori K. et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J. Orthop. Res. 2005, v. 23, No. 5, p. 979-987.Nishimura M., Yuasa K., Mori K. et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J. Orthop. Res. 2005, v. 23, No. 5, p. 979-987.Pedersen K.B., Andersen K., Fodstad O., Maelandsmo G.M. Sensitization of interferon-gamma induced apoptosis in human osteosarcom a cells by extracellular S100A4. BMC Cancer. 2004, No. 4, p. 52.Salvi D., Kiyokawa H., Colamonici O.R. et al. Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope. Pediatr. Hematol. Oncol. 2005, v. 22, No. 4, p. 297-308.Sandoval R., Xue J., Pilkinton M. et al. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J. Biol. Chem. 2004, v. 279, No. 31, p. 32275-32280.Sato T., Onai N., Yoshihara H. et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat. Med. 2009, v. 15, No. 6, p. 696-700.Strander H. Interferons and osteosarcoma. Cytokine Growth Factor Rev. 2007, v. 18, No. 5-6, p. 373-380.Wenner C.A., Gueler M.L., Macatonia S.E. et al. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J. Immunol. 1996, v. 156, No. 4, p. 1442-1447.Yamano Y., Araya N., Sato T. et al. Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One. 2009, v. 4, No. 8, E. 6517.Young H.A., Hardy K.J. Role of interferon-gamma in immune cell regulation. J. Leukoc. Biol. 1995, v. 58, No. 4, p. 373-381